TOMI Expands Globally with Purchase from National Health Services (NHS) Wales
TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ) has announced that NHS Wales has purchased their SteraMist ionized Hydrogen Peroxide (iHP) technology, marking a significant step in expanding their footprint in Great Britain. The NHS Wales aims to enhance its aseptic pharmaceutical manufacturing capabilities, finding traditional cleaning methods cumbersome for large facilities. The purchase includes a SteraMist Environment System, which NHS Wales reported will improve the quality of medicines supplied to patients. TOMI continues to grow its international partnerships, with purchases from various countries, making its SteraMist solutions accessible globally.
- NHS Wales purchased SteraMist ionized Hydrogen Peroxide technology, expanding TOMI's presence in Great Britain.
- The SteraMist system is expected to improve the quality of medicines supplied by NHS Wales.
- TOMI is enhancing its international partnerships with ongoing purchases from countries like the UK, Australia, and Germany.
- None.
FREDERICK, Md., Jan. 17, 2023 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, announces that the National Health Services (NHS) Wales purchased SteraMist ionized Hydrogen Peroxide (iHP) technology further expanding presence in Great Britain.
NHS Wales is a publicly funded healthcare system in Wales that provides emergency services as well as primary, secondary, specialist services, and funding for other healthcare service initiatives. NHS Wales is currently constructing facilities mainly for the expansion of their aseptic pharmaceutical manufacturing. Traditional, manual cleaning has proven to be time consuming and difficult for these large-scaled buildings and with the ease of use and quick disinfection, NHS Wales purchased their first SteraMist Environment System.
Immediately after receiving the full room fogger, they took to social media with their excitement for their new SteraMist iHP system and stated it will “further improve quality of medicines we supply to patients.” As they continue to expand, there is a potential for additional purchases in the near future including a Custom Engineered System (CES).
TOMI continues to increase its presence and maintain strong partnerships and distributors of SteraMist disinfection throughout the world. Many of our longstanding international partners continue to make SteraMist purchases in 2022 in the United Kingdom, Australia, Panama, Germany, Hong Kong, and Singapore. TOMI has brought on additional international partners this year in Poland, Jamacia, and Nigeria. With the variety of SteraMist systems, TOMI can accommodate budgets to fit the country’s needs, making SteraMist disinfection accessible to everyone throughout the world.
TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®
TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology ® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage hydrogen peroxide as its only active ingredient and uses patented ionized Hydrogen Peroxide (iHP™) technology in all SteraMist systems to create superior disinfection. TOMI products are designed to service a broad spectrum of use sites, including, but not limited to, hospitals and medical facilities, biosafety labs, pharmaceutical facilities, commercial and office buildings, schools, restaurants, meat and produce processing facilities, and police and fire departments.
For additional information, please visit http://www.tomimist.com/ or contact us at info@tomimist.com
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to international expansion of TOMI’s business operations. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, the impact of COVID-19 pandemic on our business and customers; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.
INVESTOR RELATIONS CONTACT:
John Nesbett/Jennifer Belodeau
IMS Investor Relations
tomi@imsinvestorrelations.com
FAQ
What recent purchase did NHS Wales make from TOMI?
How will NHS Wales's purchase affect patient care?
What is the significance of TOMI's expansion into Great Britain?
What technology is included in the SteraMist system?
Which other countries have purchased SteraMist products from TOMI?
